Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its cutting edge find platform, today announced that an oral beneficence of data for delafloxacin, its lead antibiotic candidate, will be given at the 20th continental crowd of Clinical Microbiology and epidemic Diseases (ECCMID), April 10-14, in Vienna, Austria by Paul G. Ambrose, Pharm.D, FIDSA, Director, standard for Clinical Pharmacodynamics, Ordway delving Institute.

More: - From the site